Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Co-transplantation of pancreatic islets with adipose-derived mesenchymal stem cells in vascularized kidney ECM scaffolds to restore type 1 diabetes mellitus.

Choi M., Shanto PC., Fahad MAA., Bae SH., Lee BT.

Animal Study on Type 1 Diabetes, Scar, Immune Modulation, published in Bioact Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Bioact Mater (2026)
Country
China
Reported sample size
—
Source database
PubMed
PMID
42306051
PMCID
PMC13265688
DOI
10.1016/j.bioactmat.2026.03.001

Abstract (original English)

Type 1 diabetes mellitus (T1DM) requires innovative strategies to restore insulin production while overcoming immune rejection and limited donor availability. In this study, we developed a bioengineered insulin-producing tissue (IPT) by combining isolated pancreatic islets with adipose-derived stem cells (ADSCs) on a decellularized kidney extracellular matrix (k-ECM). Instead of discarding the substandard conditions islets, we demonstrate that they provide valuable bioactive signals like cytokines, growth factors, and extracellular matrix cues, which promote ADSCs differentiation into functional insulin-producing cells (IPCs). Moreover, the vascularized microstructure of k-ECM closely resembles pancreatic tissue, further supporting islet viability, and the co-culture of islets with ADSCs promotes revascularization and immunomodulation. In vitro results demonstrated that islet/ADSC/k-ECM enhances structural support, insulin secretion, and ADSC differentiation into IPCs. In vivo implantation of the islet/ADSC/k-ECM construct in a rat T1DM model restored fasting blood glucose (FBS), increased insulin secretion, angiogenesis, muscle thickness, immunomodulatory effects, and differentiation of ADSCs into IPCs, confirmed by immunohistochemistry (IHC) and RNA-seq. Collectively, this study demonstrates that the islet/ADSC/k-ECM (ILAE) construct creates a vascularized, insulin-producing,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research